🇺🇸 FDA
Patent

US 11116838

Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy

granted A61KA61K2039/505A61K2039/53

Quick answer

US patent 11116838 (Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy) held by Inovio Pharmaceuticals, Inc. expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Inovio Pharmaceuticals, Inc.
Grant date
Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K2039/505, A61K2039/53, A61K2039/545, A61K2039/585